Envista (NVST) Stock Forecast & Price Target

$18.70 +0.67 (+3.72%)

(As of 12/20/2024 05:31 PM ET)

Envista - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 16 Analyst Ratings

Sell
2

Hold
11

Buy
3

Based on 16 Wall Street analysts who have issued ratings for Envista in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 2 have given a sell rating, 11 have given a hold rating, and 3 have given a buy rating for NVST.

Consensus Price Target

$20.65
10.45% Upside

According to the 16 analysts' twelve-month price targets for Envista, the average price target is $20.65. The highest price target for NVST is $26.00, while the lowest price target for NVST is $16.00. The average price target represents a forecasted upside of 10.45% from the current price of $18.70.

Get the Latest News and Ratings for NVST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Envista and its competitors.

NVST Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	11 Hold rating(s)	11 Hold rating(s)	8 Hold rating(s)	3 Hold rating(s)
Sell	2 Sell rating(s)	1 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$20.65	$20.71	$19.59	$33.88
Forecasted Upside	10.45% Upside	-3.59% Downside	2.89% Upside	40.04% Upside
Consensus Rating	Hold	Hold	Hold	Hold

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

NVST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Envista Stock vs. The Competition

Type	Envista	Medical Companies	S&P 500
Consensus Rating Score	2.06	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	10.45% Upside	25,828.18% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent NVST News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/4/2024	Mizuho 3 of 5 stars	S. Valiquette Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$20.00	-9.05%
10/31/2024	Leerink Partnrs 5 of 5 stars	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
10/31/2024	Piper Sandler 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$16.00 ➝ $17.00	-19.96%
10/31/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
10/31/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$17.00 ➝ $22.00	+14.58%
10/31/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform	$16.00 ➝ $23.00	+19.79%
Your bank is lying to you. (Ad) You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts. View the best savings account rates here
10/23/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$18.00 ➝ $21.00	+12.90%
10/8/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	V. Chopra Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$20.00	+9.59%
9/23/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$18.00 ➝ $23.00	+18.92%
8/8/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$22.00 ➝ $19.00	+16.78%
8/8/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$23.00 ➝ $16.00	+4.58%
5/3/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sell ➝ Sell	$20.00 ➝ $17.50	-8.71%
4/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$33.00 ➝ $21.00	+4.90%
2/9/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$30.00 ➝ $23.00	+2.54%
2/8/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Vazquez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
1/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$26.00	+11.21%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:13 AM ET.

NVST Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Envista is $20.65, with a high forecast of $26.00 and a low forecast of $16.00.
: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Envista in the last year. There are currently 2 sell ratings, 11 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVST shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVST, but not buy additional shares or sell existing shares.
: According to analysts, Envista's stock has a predicted upside of 10.45% based on their 12-month stock forecasts.
: Over the previous 90 days, Envista's stock had 2 upgrades by analysts.
: Envista has been rated by research analysts at Evercore ISI, Leerink Partners, Leerink Partnrs, Mizuho, Needham & Company LLC, Piper Sandler, Robert W. Baird, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.
: Analysts like Envista less than other "medical" companies. The consensus rating for Envista is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVST compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

This page (NYSE:NVST) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Envista (NVST) Stock Forecast & Price Target